Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites

(1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed. However, it is still unclear whether this novel drug may improve long-term survival rates in cirrhotic patients with ascites....

Descripción completa

Detalles Bibliográficos
Autores principales: Hosui, Atsushi, Tanimoto, Takafumi, Okahara, Toru, Ashida, Munehiro, Ohnishi, Kohsaku, Wakahara, Yuhhei, Kusumoto, Yukihiro, Yamaguchi, Toshio, Sueyoshi, Yuka, Hirao, Motohiro, Yamada, Takuya, Hiramatsu, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830941/
https://www.ncbi.nlm.nih.gov/pubmed/33466878
http://dx.doi.org/10.3390/jcm10020294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830941/
https://www.ncbi.nlm.nih.gov/pubmed/33466878
http://dx.doi.org/10.3390/jcm10020294

Ejemplares similares